Trial Profile
PALbociclib CoLlaborative Adjuvant Study: A randomized phase III trial of Palbociclib with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy alone for hormone receptor positive (HR+) / human epidermal growth factor receptor 2 (HER2)-negative early breast cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 26 Jan 2024
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Early breast cancer; HER2 negative breast cancer; Male breast cancer
- Focus Therapeutic Use
- Acronyms PALLAS
- 09 Dec 2023 Results assessing Racial and Ethnic Differences in Clinical Outcomes in patients (pts) with early-stage HR+HER2- breast cancer treated with or without adjuvant palbociclib ,presented at the 46th Annual San Antonio Breast Cancer Symposium
- 09 Dec 2023 Results evaluating clinical and demographic variables associated with HER2 expression, presented at the 46th Annual San Antonio Breast Cancer Symposium
- 09 Dec 2023 Results of exploratory analysis assessing whether concomitant use of PPIs could have affected clinical outcomes in patients treated with pal, presented at the 46th Annual San Antonio Breast Cancer Symposium